Dr. Larson is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
5841 S. MARYLAND AVE.
M/C 2115
Chicago, IL 60637Phone+1 773-702-6783Fax+1 773-702-3002- Is this information wrong?
Summary
- Dr. Richard Larson is a hematologist-oncologist in Chicago, IL, and is affiliated with University of Chicago Medical Center. He received his medical degree from Stanford University School of Medicine and has been in practice >40 years. He specializes in hematologic oncology and is experienced in acute and chronic leukemia, chemotherapy, hematologic oncology, marrow transplantation and cellular therapy, and aplastic anemia.
Education & Training
- University of ChicagoFellowship, Hematology and Medical Oncology, 1980 - 1983
- University of ChicagoResidency, Internal Medicine, 1977 - 1980
- Stanford University School of MedicineClass of 1977
Certifications & Licensure
- IL State Medical License 1978 - 2026
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
- Super Doctor SuperDoctors.com
Clinical Trials
- Safety and Anti-Disease Activity of Oral Tosedostat (CHR-2797) in Elderly Subjects With Refractory or Relapsed AML Start of enrollment: 2009 Oct 01
- Study Safety and Preliminary Efficacy of DCC-2036 in Patients With Leukemias (Ph+ CML With T315I Mutation) Start of enrollment: 2009 Mar 01
- A Study That Switched Patients From Imatinib to Nilotinib and Then Was Followed by Treatment Cessation Start of enrollment: 2013 Aug 12
- Join now to see all
Publications & Presentations
PubMed
- 1 citationsAcute Lymphoblastic Leukemia with Myeloid Mutations Is a High-Risk Disease Associated with Clonal Hematopoiesis.Patel, A. A., Caner Saygin, Pu Zhang, Jacob Stauber, Ibrahim Aldoss, Adam S Sperling, Lachelle D Weeks, Marlise R Luskin, Todd C Knepper, Pankhuri Wanjari, Peng Wang, ...> ;Blood Cancer Discovery. 2024 May 1
- 1 citationsFollow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL.Barr, P. M., Barr, P. M., Barr, P. M., Jennifer A Woyach, Gabriela Perez Burbano, Amy S Ruppert, Cecelia Miller, Nyla A Heerema, Weiqiang Zhao, Anna Wall, Wei Ding, Na...> ;Blood. 2024 Apr 18
- Expedited evaluation of hereditary hematopoietic malignancies in the setting of stem cell transplantation.Gregory W Roloff, Satyajit Kosuri, Mariam T Nawas, Adam S DuVall, Anand A Patel, Peter A Riedell, Olatoyosi Odenike, Wendy Stock, Richard A Larson, Michael R Bishop, E...> ;Haematologica. 2024 Apr 11
- Join now to see all
Abstracts/Posters
- Superior Survival with Post-Remission Pediatric-Inspired Chemotherapy Compared to Myeloablative Allogeneic Hematopoietic Cell Transplantation in Adolescents and Young ...Richard A. Larson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Emerging Mutations at Relapse in Patients with FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia Who Received Gilteritinib Therapy in the Phase 3 Admiral TrialCl...Richard A. Larson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Outcomes of IDH-Mutated Advanced Phase Ph-Negative Myeloproliferative Neoplasms Treated with IDH InhibitorsRichard A. Larson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Lectures
- Allogeneic Hematopoietic Cell Transplantation (HCT) Vs. Non-HCT Consolidation Therapies in Acute Myeloid Leukemia (AML) Patients 60-75 Years of Age in First Complete R...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- ABL Tyrosine Kinase Inhibitors (TKIs) Are Associated with Increased Rho-Associated Kinase (ROCK) Activity That May Contribute to Vascular Toxicity in Patients with Chr...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Comprehensive Molecular Profiling of FLT3-Mutated Acute Myeloid Leukemia (AML) Patients Treated within the Ratify Trial (Alliance C10603)2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Join now to see all
Authored Content
- Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 MutationJune 2017
Press Mentions
- 1st Patient Dosed with Cellectis’ Allogeneic UCART22 in Relapsed/Refractory B-cell Acute Lymphoblastic LeukemiaDecember 2nd, 2019
- Uchicago Medicine Oncologist to Receive 2019 Henry M. Stratton Medal for Hematology ResearchAugust 13th, 2019
Professional Memberships
- Member
- Member
- Member
Hospital Affiliations
- University of Chicago Medical CenterChicago, Illinois
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: